A randomized, double-blind, placebo-controlled Phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of ZYOG1, a novel GLP-1 agonist, following oral administration in healthy volunteers.

Trial Profile

A randomized, double-blind, placebo-controlled Phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of ZYOG1, a novel GLP-1 agonist, following oral administration in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs ZY OG1 (Primary)
  • Indications Diabetes mellitus; Obesity
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Cadila Healthcare
  • Most Recent Events

    • 24 Aug 2016 Last checked against Clinical Trials Registry - India record.
    • 08 Sep 2010 Status changed from planning to recruiting as reported by Clinical Trials Registry - India record.
    • 13 Jul 2010 Additional location (India) added, primary outcome amended, actual initiation date (28 Jun 2010) added as reported by Clinical Trials Registry - India.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top